Atypical Chemokine Receptor 1 Polymorphism can not Affect Susceptibility to Hepatitis C Virus

• Published in: Balkan medical journal 2017-07, Vol.34 (4), p.308-312
• Main Authors: Zhang, Shu Ting, Shi, Ming, Shao, Lin Nan, Zhou, Shi Hang, Yu, Wei Jian, Chen, Mei, Xiao, Nan, Duan, Ying, Pan, Ling Zi, Wang, Ni, Song, Wen Qian, Xia, Yue Xin, Zhang, Li, Qi, Ning, Liu, Ming
• Format: Article
• Language: English
• Subjects: Adult; Atypical chemokine receptor 1; Case-Control Studies; Chemokine receptors; Duffy Blood-Group System - genetics; Female; Genetic aspects; Genetic polymorphisms; Genetic Predisposition to Disease - genetics; Hepacivirus - genetics; Hepacivirus - immunology; Hepacivirus - pathogenicity; Hepatitis C virus; Humans; Male; Middle Aged; Original; polymorphism; Polymorphism, Genetic - genetics; Receptors, Cell Surface - genetics; susceptibility; Tıp
• ISSN: 2146-3123; 2146-3131
• DOI: 10.4274/balkanmedj.2016.0766

Hepatitis C virus has infected 130 to 150 million individuals globally. Atypical chemokine receptor 1 has become a focus of research because of its diverse roles in different diseases. However, little is known regarding the association of atypical chemokine receptor 1 polymorphism with susceptibility to hepatitis C virus. To determine the association of an atypical chemokine receptor 1 polymorphism (rs12075) with hepatitis C virus susceptibility. Case-control study. We collected blood samples from 231 patients infected with hepatitis C virus and 239 blood donors as control subjects. Genotyping of atypical chemokine receptor 1 was performed using a 5'-nuclease assay with TaqMan-minor groove binding probes. Comparisons between hepatitis C virus-infected patients and control subjects were assessed using Fisher's exact test. The genotype frequencies of FY*A/FY*A, FY*A/FY*B and FY*B/FY*B were 86.1%, 13.9% and 0% in the patient group, and 86.2%, 13.4% and 0.4% in the control group, respectively. The difference in atypical chemokine receptor 1 genotype frequencies between hepatitis C virus-infected patients and control group was not significant (p=1.00, OR=1.004, 95% CI=0.594-1.695). FY*A and FY*B allele frequencies were 93.1% and 6.9% in the patient group, and 92.9% and 7.1% in the control group, respectively. The difference in atypical chemokine receptor 1 allele frequencies between hepatitis C virus-infected patients and the control group was not significant (p=1.00, OR=0.972, 95% CI=0.589-1.603). Our result indicates that atypical chemokine receptor 1 polymorphism (rs12075) does not affect susceptibility to hepatitis C virus.